Unfortunately the recent FDA approval of two marginally efficacious, expensive and dangerous MABs only encourages more trials with the same objective.
They will never be the effective, low side effect and cheap oral medication that Blarcamasine offers yet they keep dumping billions into chasing the same unicorn over and over.
Unfortunately, a failure in biotech has no impact on a another's approval. Only the data can prove useful or not. I wish it were the case because the it would be in the bag...but Rett was in the bag once
Market Data 
Markets 
AI
